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Abstract
Background: Eliminating mother-to-child transmission of HIV is a global public health target. Robust, feasible
methodologies to measure population level impact of programmes to prevent mother-to-child transmission of HIV
(PMTCT) are needed in high HIV prevalence settings. We present a summary of the protocol of the South African
PMTCT Evaluation (SAPMTCTE) with its revision over three repeated rounds of the survey, 2010–2014.
Methods: Three cross sectional surveys (2010, 2011–2012 and 2012–2013) were conducted in 580 primary health
care immunisation service points randomly selected after stratified multistage probability proportional to size
sampling. All infants aged 4–8 weeks receiving their six-week immunisation at a sampled facility on the day of the
visit were eligible to participate. Trained research nurses conducted interviews and took infant dried blood spot
(iDBS) samples for HIV enzyme immunoassay (EIA) and total nucleic acid polymerase chain reaction (PCR) testing.
Interviews were conducted using mobile phones and iDBS were sent to the National Health Laboratory for testing.
All findings were adjusted for study design, non-response, and weighted for number of South African live-birth in
each study round. In 2012 a national closed cohort of these 4 to 8-week old infants testing EIA positive (HIV
Exposed Infants) from the 2012–2013 cross-sectional survey was established to estimate longer-term PMTCT impact
to 18 months. Follow-up analyses were to estimate weighted cumulative MTCT until 18 months, postnatal MTCT
from 6 weeks until 18 months and a combined outcome of MTCT-or-death, using a competing risks model, with
death as a competing risk. HIV-free survival was defined as a child surviving and HIV-negative up to 18 months or
last visit seen. A weighted cumulative incidence analysis was conducted, adjusting for survey design effects.
Discussion: In the absence of robust high-quality routine medical recording systems, in the context of a generalised
HIV epidemic, national surveys can be used to monitor PMTCT effectiveness; however, monitoring long-term outcomes
nationally is difficult due to poor retention in care.
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Background
In 2010 the WHO Global Elimination of Maternal to
Child Transmission of HIV (MTCT) Initiative aimed to
reduce new paediatric HIV infections by 90% by 2015
from the 2009 estimated baseline, and reduce the overall
population-based HIV transmission rate through MTCT
to < 5% (< 2% in the absence of breastfeeding) [1]. In
2011 the Global Plan to prevent MTCT and keep
mothers alive was launched, identifying 21 Global Plan
priority countries where 90% of the worlds’ HIV-positive
pregnant women reside [2].
South Africa is defined as a high HIV prevalence
country, with antenatal HIV prevalence of approximately
29.5% (95% confidence interval, 28.8–30.2), ranging from
16.9 to 37.4 across the nine provinces, and a commit-
ment to reducing vertical HIV transmission [3–6]. In
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2001, South Africa started implementing a programme
to prevent HIV transmission from mother-to-child
(PMTCT) at 18-pilot sites using a single dose Nevirapine
(Sd-NVP) regimen for the mother during labour and to
the baby within 72 h of delivery; modified obstetric prac-
tices; infant feeding counselling and the provision of free
commercial infant formula to HIV-positive mothers who
avoided breastfeeding [5]. The Sd-NVP PMTCT inter-
ventions were scaled up nationally in 2002 [6]. In 2008
the national antiretroviral regimens for pregnant women
were changed to a dual therapy regimen defined as
Azidothymidine (AZT) from 28 weeks with Sd-NVP at
the outset of labour for pregnant women and Sd-NVP
with AZT for baby [7].
In 2010, PMTCT interventions were further modified
to include routine HIV testing and counselling for all
pregnant women, and maternal triple antiretroviral ther-
apy (ART) for pregnant women with CD4 cell count
≤350 cells/μl, or dual therapy from 14 weeks for those
with ≤350 cells/μl, and postnatal infant prophylaxis for 6
weeks in non-breastfeeding infants or throughout the
breastfeeding period (termed WHO Option A) [8]. In
2013 South Africa adopted WHO Option B (lifelong
ART for all HIV positive pregnant women who require
it for their own disease or through the end of breastfeed-
ing for women with CD4 cell counts >350cells/mm3) [9].
In 2015 WHO Option B was extended to WHO Option
B+, which recommended lifelong ART for all HIV posi-
tive pregnant and lactating women [10]. National guide-
lines recommended HIV PCR testing of all HIV-exposed
infants at six-weeks, post breastfeeding cessations and
18months post-delivery; however, with the adoption of
PMTCT Option B+ HIV, PCR testing of infants was
recommended at birth, 10 weeks, 6 weeks after breast-
feeding cessation and 18months [10].
Within 10 years of implementing the South African
PMTCT program, national coverage increased to 95% of
antenatal and maternity facilities by 2010. Between 2001
and 2010, data sources for PMTCT effectiveness assess-
ments included: a) small scale evaluations in selected
sites [11, 12], b) review of routine PCR positivity data
from the National Health Laboratory Services (NHLS)
[13] and c) review of routine data from the District
Health Information system (DHIS) [14]. The small-scale
surveys lacked a national footprint; the NHLS routine
data potentially had selection bias in that it only reports
on infants accessing testing, whilst the DHIS data lacked
valid denominators to calculate transmission reliably.
Consequently, there was a dire need to measure national
PMTCT effectiveness by 2010. Therefore, the South
African Medical Research Council, in collaboration with
the South African National Department of Health,
National Health Laboratory Services, CDC-PEPFAR,
UNICEF and the University of the Western Cape,
planned and implemented three national probability-
based cross-sectional surveys in 2010, 2011 and 2012–13
to measure early national and provincial MTCT rates
and a national cohort study in 2012–2014 to measure
18-month MTCT and HIV-free survival, to assess early
and long term impact of the South African National
PMTCT Programme.
This paper presents an overview of the South African
PMTCT Evaluation (SAPMTCTE) protocol, covering
both the cross-sectional and cohort components.
Aims of the SAPMTCTE
We aimed to periodically measure the effectiveness and im-
pact of the South African national PMTCT programme on
mother-to-child transmission of HIV (MTCT), with surveys
planned in 2010, 2011–12 and 2012–13. In 2012–13, we
added additional primary objectives, which were to measure
the cumulative MTCT from 6-weeks post-partum through
18months post-delivery and HIV-free survival among a na-
tional cohort of infants born to HIV-positive mothers.
Secondary objectives of the surveys were to: a) esti-
mate coverage of key PMTCT interventions and services
(e.g. HIV testing, CD4 cell count testing, infant ARV
prophylaxis, counselling on infant feeding); b) estimate
the association between MTCT rate and ARV regimen,
maternal background characteristics including CD4 cell
count, maternal health care services and maternal and
infant health status; c) measure uptake of HIV care-and-
treatment referral services for HIV-infected pregnant
women, infant post-test counselling and HIV-infected
children who are diagnosed at primary health care
setting; d) measure the impact of maternal ART or ma-
ternal/infant antiretroviral (ARV) prophylaxis on growth
in the cohort of HIV exposed uninfected (HEU) infants
up to 18 months; and e) identify potential factors associ-
ated with loss to follow up from the HEU cohort.
Methods/design
Study design and sampling frame
Cross-sectional national probability-based primary health
care facility-based surveys, using an HIV biomedical
marker (HIV antibody testing) to determine infant HIV
exposure, and a virological test to measure perinatal HIV
transmission amongst biomarker positive (HIV exposed)
infants (HEI) were conducted at 4–8 weeks post-delivery
from June–December 2010, August 2011–March 2012
and October 2012–May 2013 [15, 16].
The sampling frame for the primary sampling units
(PSU) were public (government-funded) Primary Health
Care (PHC) clinics and Community Health Centres
(CHC) reportedly administering six-week immunisations
(DPT1 or Pentaxim1 or the hexavalent vaccine), as doc-
umented in the South African National District Health
Information System (DHIS). While other public facilities
Jackson et al. BMC Infectious Diseases 2019, 19(Suppl 1):784 Page 2 of 8
do administer immunizations (hospitals, mobile clinics),
these PHC clinics and CHC are the primary locations
for routine primary child health services. Data from the
2007 DHIS was used to obtain this sampling frame of
eligible facilities and included the number of DTP1 ad-
ministrations done in each facility for that year.
The sampling design was stratified by the nine prov-
inces. Eligible facilities were stratified on the number of
annual immunizations reported with three strata based
on reported annual DTP1 administration: < 130, 130–300
and > 300 immunizations per annum. The stratum of the
small facilities (< 130 immunizations per annum) con-
sisted of 951 facilities performing 67,514 immunizations
per annum which represented 7.0% of the total immuniza-
tions done in 2007 in South Africa. For fieldwork cost-effi-
ciency, a strategic decision was taken to exclude this
stratum from the formal sample. The National Department
of Health expressed an interest in the efficiency of the
PMTCT in facilities with high prevalence and high
birth rates. To accommodate this request, facilities
with > 300 immunizations per annum in the sampling
frame were also stratified in two strata (≥29% or < 29%)
based on the 2008 HIV national antenatal prevalence of
29%, using the district HIV prevalence in which they were
based.
A two-stage stratified sampling was used. In the first
stage, facilities (primary sampling units - PSUs) were
randomly sampled proportional to size (PPS) within
each of the 27 (9 provinces X 3 facility size/HIV preva-
lence) stratum (see Fig. 1). The method operated under
the with-replacement-type selection [17]. At the second
stage, a fixed number of infants per facility was system-
atically sampled. The fixed number was the median
number of infants expected within the sampling window
(3 weeks) across the population of facilities within the
stratum as determined from the detailed information of
the sampling frame above. The fixed number of infants
sampled in each facility within a stratum ensured a self-
weighting sample. A sampling window of 3 weeks was
used to realize the required sample. Five hundred eighty
facilities were sampled (approximately 21–22 per strata).
More detail on sampling methods have been published by
Goga, et al. 2014 & 2016 and Dinh, et al. 2015 [15, 16, 18].
From the 2012–13 survey, HEU infants were invited
to participate in a closed, prospective observational
18-month follow-up study. Establishing and following-
up the cohort entailed recruitment into the follow-up
study at the time of the six-week interview, documenting
detailed participant contact information (including ad-
dress) in a protected web-based data base that only the
allocated data collector had access to, and allowing home-
based data collection and an inconvenience allowance of
approximately 10 USD. HEU were followed up at 3, 6, 9,
12, 15 and 18months to determine maternal and child
access to care and MTCT. HIV infected children were
followed up once after HIV positive diagnosis to deter-
mine access to HIV treatment. If the infant had not yet
accessed care, appropriate referrals were made.
Study population
The cross-sectional survey was conducted among all
mother/legal caregiver-infant pairs (97% were biological
mother) who presented at their local primary health care
facility for their infant’s six-week immunisation (1st
DTP dose) visit, regardless of their PMTCT status or
HIV exposure. South Africa reports > 95% coverage of 6
week immunisation (1stDTP dose) [19], making these
clinics an ideal catchment point for young infants.
Fig. 1 Sampling Frame
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Infants accessing selected public primary health care
clinics or community health centres were eligible for the
cross-sectional surveys if they were: a) receiving their
six-week immunization on the day of data collection,
and b) 4–8 weeks old, c) did not need emergency med-
ical care, and d) their mother/legal caregiver consented
to participate in the survey. Infants were enrolled into
follow-up if: a) their mother reported as being HIV posi-
tive and/or their HIV antibody test was positive, and b)
they consented to follow-up. Infants remained eligible
for on-going follow-up until 18 months if their PCR tests
remained negative (i.e. HIV exposed uninfected infants).
As noted above, if the infant PCR was positive at 6 weeks
or became positive at any follow-up visit they received
one additional follow-up visit to assess access to paediat-
ric treatment, with appropriate referrals if infants had
not accessed HIV care.
Sample size
To determine the sample size for each province, HIV
prevalence was calculated based on the provincial ante-
natal survey prevalence and coverage of PMTCT ARV
prophylaxis. Estimates of transmission rates for Sd-NVP
and no treatment were taken from Rollins [12] while the
transmission rate for dual therapy came from a provin-
cial survey from KwaZulu Natal province (unpublished
data, 2009).
To balance samples across the nine provinces, absolute
precision specified varied from 1 to 2%, with relative
precisions of 22 to 60%. In general, provinces with a
higher prevalence will have a lower (better) relative
precision. These specifications resulted in better equity
in sample size between provinces. Using this approach,
the largest sample in a province was 1800 (Gauteng) and
the smallest was 700 (Northern Cape) with a total sam-
ple size of 12,200 across all provinces (Table 1).
Table 2 illustrates the sample size calculation for valid
national estimates of 18 month MTCT and HIV-free
survival. The red box in Table 2 highlights the target
sample size selected for 18-month MTCT, and the green
box highlights the target sample size selected for HIV-
free survival estimates. These calculations demonstrated
that assuming a design effect of 2, 18-month MTCT of
5% (3.5–6.5%) and 10% (7–13%) HIV infection or death,
1620 infants were needed to estimate MTCT and 768 in-
fants are needed to estimate HIV infection or death with
the indicated precision. Assuming 30% loss to follow-up,
2314 infants needed to be enrolled into the follow-up
study to estimate both MTCT and HIV-free survival.
Data collection and study tools
Trained nurse data collectors recruited mothers/care-
givers from the PHC/CHC waiting room during immun-
isation days. Data collectors introduced themselves and
the study verbally and in written form using a standar-
dised information sheet. A screening questionnaire was
administered to determine eligibility and then full in-
formed consent was completed for eligible infants (see
below). If an eligible mother/legal caregiver-infant pair
agreed to be interviewed, the interview was conducted in
a private location.
Table 1 Sample size calculation for the cross-sectional surveys
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Data were gathered using a questionnaire adapted
from several validated tools [11, 12, 20]. The question-
naire included information on maternal age, parity,
socio-economic status, antenatal care, HIV testing,
maternal HIV status, PMTCT care during pregnancy
and delivery, infant feeding counseling, birth informa-
tion, infant feeding practices, infant weight; immunisa-
tions, postnatal visits and illness since birth. Legal (non-
maternal) caregivers were administered a shorter version of
the questionnaire that excluded antenatal care and PMTCT
programme information.
Trained research nurses also collected infant heel prick
dried blood spot samples during infant immunization
visits, from all consented infants, regardless of reported
maternal HIV status or ARV exposure. The blood testing
replaced the routine testing for HIV PCR as part of the
PMTCT programme during the period of the study as it
was felt to be inappropriate to bleed a child twice during
the same clinic visit. Trained research nurses worked from
immunization clinics to facilitate standardization of pro-
cedure and data quality control. They offered routine HIV
testing to all infants attending the clinic for immunization,
thus preventing the testing of a potentially biased sample
of infants: routine PMTCT EID clinics only test known
HIV-exposed infants. Additionally, we found that mater-
nal request for early infant diagnosis of HIV infection
(EID) during the routine immunization services were low
(47%) [21]. The mothers/caregivers were informed that
the infant testing would also act as a biomedical marker
for HIV status of the mother and that she may need to
have further follow-up including HIV counselling and
testing (HCT).
For the cohort study, the same trained research nurses
used contact details obtained at cohort enrollment to
arrange to meet the mother/legal caregiver-infant pairs
during routine follow-up for all HEU at the health
facility at 3, 6, 9, 12, 15 and 18months. Interviews were
completed and iDBS were taken for HIV PCR at 3, 6, 9,
12 and 15months as the national guidelines did not
recommend routine blood testing during these visits.
During the 18month visit the routine in-clinic HIV rapid
test was used to document 18-month infant HIV status.
The iDBS were sent to a centralized accredited laboratory
(National Institute for Communicable Diseases, a division
of the National Health Laboratory services) for HIV
enzyme immunoassay (EIA) testing, followed by HIV total
nucleic acid polymerase chain reaction (TNA PCR) testing
on EIA positive samples. All EIA positive samples were
serially tested for HIV infection with a second HIV EIA
test, and 10% of negative samples were re-tested using a
second test. Discordant first and second EIA test re-
sults underwent additional testing using Western Blot.
Details about laboratory procedures have been pub-
lished previously [15, 16].
Questionnaire data were entered in a mobile phone
platform and transferred electronically to a central
Table 2 Sample size calculation for follow-up component
Footnote: The bolded boxes highlight the sample sizes selected to estimate HIV infection or death (green box) or 18-month MTCT only (red box), with 30%
precision, a design effect of 2 and assuming 20 or 30% loss to follow-up. These show that assuming a design effect of 2, 18-month MTCT of 5% (3.5–6.5%) and
10% (7–13%) MTCT or death, 1620 infants are needed to estimate MTCT and 768 infants are needed to estimate HIV or death. Assuming 30% loss to follow-up,
2314 infants need to be enrolled to estimate MTCT and HIV-free survival. Sample size calculations were made using standard nQuery Version 4.0
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server for data management and data analysis. This is
described in detail in another paper in this supplement
[Ref pending].
Ethics
The Ethics Committee of the South African Medical
Research Council (SAMRC), provincial Ethics Committees,
and the Centers for Disease Control and Prevention,
Atlanta, approved the study protocol. All eligible mothers/
primary caregivers (14+ years of age) were taken through a
written informed consent process. Pregnant adolescents
age 14–17 are considered emancipated minors in South
Africa and were eligible for study participation. The process
was conducted in the language of the participant and infor-
mation sheets were translated into all South African official
11 languages. Consent forms were completed in duplicate,
and one copy was given to the participant and confidential-
ity discussed and the other sent to the SAMRC offices. At
the end of the interview, if the mother reported being HIV-
positive and hence eligible for the follow-up study, a second
consent process was conducted, followed by the completion
of a second consent form. A participant contact informa-
tion form was completed for all participants who agreed to
follow-up and this was stored in a password protected data-
base and could only be accessed by the data collector allo-
cated to that participant. All mothers and infants were
referred into care (routine maternal HIV testing or CD4
cell count testing or ART) as appropriate using referral
cards which stipulated the exact, most convenient and ap-
propriate routine health care setting that could to be
accessed for further care. These sites were determined fol-
lowing a situational assessment conducted prior to the sur-
veys. Determining appropriate referral sites for each study
clinic and establishing referral protocols for HIV-positive
mothers and infants is an important ethical consideration
for any PMTCT evaluation. If this information is not
already established, then a situational assessment to map
referral sites may be needed prior to PMTCT study imple-
mentation [21].
Data analysis and sample weighting
Sample weights were calculated for the cross-sectional
surveys to adjust for differential sampling design across
provinces and the sample realization. To achieve this,
the data from provinces were weighted by using the pro-
portional distribution of live births per province re-
corded in 2008. The realisation weights were done at
various levels (district, provincial) depending on the
sample size realisation within strata. All findings were
adjusted for study design, non-response, and weighted
for number of South African live-birth in each study
round.
For the cohort study, longitudinal data were weighted
for ‘no consent’ and ‘loss to follow-up’ amongst HIV
exposed uninfected infants eligible for follow-up. Fol-
low-up analyses were to estimate weighted cumulative
MTCT until 18 months, postnatal MTCT from 6 weeks
until 18 months and a combined outcome of MTCT-or-
death, using a competing risks model, with death as a
competing risk. HIV-free survival was defined as a child
surviving and HIV-negative up to 18 months or last visit
seen. A weighted cumulative incidence analysis was con-
ducted, adjusting for survey design effects.
Specific details of each analysis will vary depending on
analysis objective, but will generally include both de-
scriptive (rates, means, 95% confidence intervals) and
analytic analyses (chi-square, ANOVA or logistic regres-
sion, with 95% confidence intervals around adjusted
estimates).
Discussion
Several global working groups have published pros and
cons of various methodologies which could be consid-
ered for evaluating PMTCT impact [22, 23]. The first
publication in 2012 [22] reviewed in detail a variety of
potential methods for measuring impact of PMTCT pro-
grammes, including: modelling, facility-based survey and
follow-up, cohort/follow-up data, population-based
household surveys, and analysis of early infant diagnosis
and child HIV testing data. The 2015 guidance focuses
more on monitoring and evaluation frameworks, includ-
ing impact evaluations [23]. The 2015 guidance high-
lights the advantages of routine cohort data for
measuring long term PMTCT programme impact if the
following conditions are met: unique identifiers, HEI
HIV PCR results available, with > 80% retention in care
and analysis of final infant outcome data. These two
guidance documents can assist potential evaluators to
make decisions about what methodology or mixture of
methodologies to employ to answer defined evaluation
questions [22, 23].
Main aims of the SAPMTCTE
The SAPMTCTE protocol outlined in this paper aimed
to measure MTCT, HIV-free survival and PMTCT
programme outcomes at national and provincial levels,
used a facility and probability based survey method with
infants attending public child health services, and was
conducted as an independent evaluation, outside of rou-
tine systems using mobile electronic data collection.
Limitations of cross-sectional and cohort studies to
measure the impact of PMTCT programmes
Limitations of the cross-sectional SAPMTCTE must be
recognized as it serves as a baseline for the follow-up
component. The data were primary facility-based using
infants presenting for immunization and routine care-
services for HIV-exposed children. Infants who did not
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come for immunization or had already died by 6 weeks
of age or attended private hospital/clinic for care were
not included in the sample suggesting a possible selec-
tion bias over-estimating PMTCT effectiveness.
Mothers may have not accurately reported or docu-
mented HIV status or ARV adherence practices for a
variety of reasons, such as fear of stigma and disclosure.
Confidentiality was assured and discussed as part of the
informed consent process and a private place was se-
cured for the conduct of interviews to reduce this poten-
tial limitation. A strength of the study was that maternal
HIV infection was based on both self-report of HIV sta-
tus and presence of HIV antibodies in infant ELISA test.
This allows for detection of infant HIV exposure even
when mothers reported HIV negative, due to hesitance
to report HIV status or due to incident infection during
pregnancy.
The main limitation of the prospective follow-up com-
ponent, which was conducted within a routine care sys-
tem, was no consent for participation in the follow-up
component and loss-to-follow up amongst those who
agreed to participate. However, we factored in loss-to-
follow up rate into our sample size calculation, and
weighted the data for no consent and loss to follow up.
We were not able to predict the directions of this bias.
Furthermore, we relied on self-reported data on infant
feeding and antiretroviral use (maternal and infant) and
did not collect drug names, dosages or blood levels to
verify reported information. We did not collect viral load
data to relate measured MTCT with maternal viral sup-
pression postnatally.
Advantages of cross-sectional and cohort studies to
measure the impact of PMTCT programmes
The strength of this approach was that this was a first
probability based national survey of MTCT which in-
cluded all provinces and all districts in South Africa fa-
cilitating national and provincial estimates and tracking
of MTCT and PMTCT programme coverage.
This study provides a robust, feasible methodology to
measure population level impact of programmes to pre-
vent mother-to-child transmission of HIV (PMTCT) in
a high HIV prevalence setting. An added advantage over
other studies is that this design provides programme
coverage and client behavior data. These are not pro-
vided by aggregated programme data or laboratory data.
Policy and programme implications
The results of surveys such as the SAPMTCTE have
guided policy and programs for PMTCT to reach an
HIV-free generation. All results were discussed during
district and provincial-level PMTCT stock-taking and
EMTCT workshops, and guided planning. Results were
also presented at PMTCT Technical working group
meetings and influences policy changes around repeat
HIV testing during pregnancy and introducing a birth
and 10 week HIV test. These methods provide both im-
pact and granular programmatic data which can be used
to improve national and provincial PMTCT program-
ming, and to target programming to achieve equitable
results for all.
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